OnLY ON-SITE REGITRATION IS NOW POSSIBLE.On-line registration is closed. |
The organizing committee cordially invites you to the 7th Status Seminar on Chemical Biology.
The conference will again present cutting-edge research at the prolific interface of chemistry and biology. This year´s topics are chemical systems biology and biologically active peptides.
PROGRAMME
Monday, December 5th 2011
Tuesday, December 6th 2011
|
|
13:00 | KEYNOTE: The dynamic Ras cycle |
H. Waldmann, Max-Planck-Institut, Dortmund/D | |
13:40 | Design of potent LRRK2 leads and elucidation of mechanism of action of novel anti-leukaemia compounds by quantitative proteomics |
C. Hopf, J. Perrin, A. Dittmann, M. Bantscheff, G. Drewes, Cellzome AG, Heidelberg/D | |
14:00 | Towards a mechanistic understanding of cell transitions, and chemotherapy response using differential analysis of high-throughput data in a network |
G. Fuellen, University of Rostock/D | |
14:20 | Combining automatic active site analysis and docking for structure-based protein function prediction. |
A. Volkamer, T. Watolla, University of Hamburg/D; F. Sonnenburg, C. Lemmen, BioSolveIT GmbH, Bonn/D; D. Kuhn, F. Rippmann, Merck Serono, Darmstadt/D; M. Rarey, University of Hamburg/D | |
14:40 | Combining virtual and biological screening for efficient lead structure identification of epigenetic targets |
W. Sippl, Universität Halle-Wittenberg/D | |
|
|
15:30 | KEYNOTE: Network pharmacology: how drug design can learn the lessons from system biology |
A. Hopkins, University of Dundee/UK |
|
16:10 |
SHORT PRESENTATION OF SELECTED POSTERS: |
P1 P3 P5 LMP3 LMP4 LMP9 |
"Synthesis of scorpion shaped glycogen synthase kinase-3 inhibitors" presented by F. Lo Monte, TU Darmstadt/D |
16:40 | KEYNOTE: From protein-chemical interaction networks to human phenotypes |
M. Kuhn, Biotec-TU Dresden/D |
|
17:20 |
Presentation of candidates |
|
|
20:00 top↑ |
General assembly of the "Fachgruppe Chemische Biologie"
|
DECEMBER 6th, 2011 Room: Carls-Duisberg |
|
09:00 | KEYNOTE: Peptide drugs - State of the art and innovative applications |
A. Beck-Sickinger, University of Leipzig/D | |
09:40 | Exploring host - Pathogen interactions using scaffolded and assembled peptides as protein binding site mimetics |
J. Eichler, A. Berthelmann, J. Meier, M. Mössl, K. Möbius, Universität Erlangen-Nürnberg/D | |
10:00 | Biomimetic screening of class B G protein-coupled receptors |
C. Devigny, B. Hoogeland, C. Cuboni, F. Hausch, MPI of Psychiatry, Munich/D | |
10:20 | A new LIM kinase inhibitor with anticancer activity, identified in a phenotype-based screen probing for microtubule stability |
R. Prudent, INSERM, Grenoble/F; E. Vassal, Grenoble/F; C.H. Nguyen, CNRS, Paris/F; S. Knapp, Oxford University/UK; O. Bernard, Melbourne University, Victoria/AUS; L. Lafanechère, CNRS, Grenoble/F | |
10:40 | Goals in chemical systems biology: how synthetic chemistry and synthetic biology complement each other in creating & studying posttranslational protein lipidation pattern |
B. Maksimovic, C. Yao, N. Mathaiyan, S. Schiller, FRIAS, Freiburg/D | |
|
|
11:30 | KEYNOTE: Discovery and applications of naturally occurring cyclic peptides in drug design |
D. Craik, University of Queensland/AUS |
|
12:10 |
New peptide natural products from entomopathogenic bacteria |
C. Dauth, H. B. Bode, Universität Frankfurt/D |
|
12:30 | Identification of novel pTyr mimetics through a fragment based dynamic ligation (DLS) screening approach |
V. Martos-Riaño, Leibniz-Institut für Molekulare Pharmakologie, Berlin/D; J. Rademann, Universität Leipzig/D |
|
12:50 |
Substrate-selective inhibition of protein kinase PDK1 with small allosteric compounds |
K. Busschots, L.A. Lopez-Garcia, C. Lammi, Universitätsklinikum Frankfurt/D; A. Stroba, University of Saarland, Saarbrücken/D; S. Zeuzem, A. Piiper, S. Neimanis, J. Arencibia, Universitätsklinikum Frankfurt/D; M. Engel, University of Saarland, Saarbrücken/D; J.O. Schulze, R.M. Biondi, Universitätsklinikum Frankfurt/D |
|
|
|
top↑ |
|
POSTER-PROGRAMME | |
P1 |
Synthesis of scorpion shaped glycogen synthase kinase-3 inhibitors |
F. Lo Monte, T. Kramer, TU Darmstadt/D; A. Fuertes, J.M. Dominguez, Noscira S.A. - Drug Discovery, Madrid/E; B. Plotkin, H. Eldar-Finkelman, Tel Aviv University/IL; B. Schmidt, TU Darmstadt/D |
|
P2 |
Peptide constructs that interfere with the Sec pathway can reduce the secretion of the pathogenicity factor V8 protease by S. aureus |
J. Al-Qudsi, Helmholtz-Centre for Infection Research, Braunschweig/D; R. Frank, Helmholtz-Centre for Infection Research and Leibniz Institute for Molecular Pharmacology, Braunschweig and Berlin/D; W. Tegge, Helmholtz-Centre for Infection Research, Braunschweig/D |
|
P3 |
Chemical biology to dissect and target the degradome of Taspase1 |
C. Bier, University Medical Center Mainz/D; L. Kunst, University Duisburg-Essen/D; R. Stauber, University Medical Center Mainz/D; S. Knauer, University Duisburg-Essen/D |
|
P4 |
Bioactive peptides derived from potato proteins |
I. Schoenbeck, S. Beutel, T. Scheper, Leibniz Universität Hannover/D |
|
P5 |
Novel inhibitors of essential viral protein-protein interactions identified by PCA in vitro |
H. Eickhoff, EMC microcollections GmbH, Tübingen/D; F. Wagner, M. Schnee, U.H. Koszinowski, Z. Ruzsics, Max von Pettenkofer Institute, München/D; K.-H. Wiesmüller, EMC microcollections GmbH, Tübingen/D |
|
P6 |
Peptide & protein based bioactive molecules and materials accessed via bionic chemistry |
M.C. Huber, C. Hege, S.M. Schiller, FRIAS, Freiburg/D |
|
P7 |
Computational prediction of enzyme activity in different buffer solutions |
K. Schomburg, University of Hamburg/D; I. Ardao, K. Götz, F. Rieckenberg, A. Liese, A.-P. Zeng, TU Hamburg-Harburg/D; M. Rarey, University of Hamburg/D |
|
P8 |
Efficient biotechnological production of a potent antimicrobial peptide |
M. Felle, S. Jenewein, BASF SE, Ludwigshafen/D |
|
P9 |
Characterization of antiviral effects of inhibitors of the cytomegalovirus nuclear egress complex |
F. Wagner, University of Munich/D; H. Eickhoff, EMC microcollections, Tübingn/D; L. Scrivano, M. Pogoda, University of Munich/D; K-H. Wiesmüller, EMC microcollections, Tübingen/D; U.H. Koszinowski, Z. Ruzsics, University of Munich/D |
|
P10 |
Vioprolid A: a potential new selective PI3Kß inhibitor |
M. Fountain, Y. Muthukumar, R. Frank, F. Sasse, Helmholtz Centre for Infection Research, Braunschweig/D |
|
P11 |
Development of the first short and linear Urotensin II analogues with biased characteristics |
S. Bandholtz, B. Wiedenmann, C. Grötzinger, Charité, Berlin/D |
|
P12 |
Site-specific covalent labelling of proteins in living cells |
T. Plass, S. Milles, C. Koehler, C. Schultz, E. Lemke, EMBL Heidelberg/D |
|
LMP1 |
Searching for new trypanothione reductase inhibitors by combining in silico and in vitro screening technologies |
M. Beig, F. Bender, O. Koch, F. Oellien, A. Rohwer, M. Gassel, Intervet Innovation GmbH, Schwabenheim/D; G. Unden, University of Mainz/D; R.L. Krauth-Siegel, University of Heidelberg/D; P.M. Selzer, Intervet Innovation GmbH, Schwabenheim/D |
|
LMP2 | A new druggable binding site in trypanothione synthetase identified via an extensive computational analysis |
O. Koch, Intervet Innovation GmbH, Schwabenheim/D; D. Cappel, M. Nocker, University of Würzburg/D; T. Jäger, L. Flohé, MOLISA GmbH, Magdeburg/D; C. Sotrifer, University of Würzburg/D; P.M. Selzer, Intervet Innovation GmbH, Schwabenheim/D |
|
LMP3 | Targeting a protein-protein interface in M. tuberculosis: first thioredoxin reductase inhibitors with high bioactivity |
O. Koch, Intervet Innovation GmbH, Schwabenheim/D; N. Doil, Medizinische Hochschule Hannover/D; F. Heller, F. Stuhlmann, S. Schmitt, D. Khandavalli, L. Schinzer, L. Flohé, MOLISA GmbH, Magdeburg/D; F.C. Bange, Medizinische Hochschule Hannover/D; T. Jäger, MOLISA GmbH, Magdeburg/D; R.J. Marhöfer, P.M. Selzer, Intervet Innovation GmbH, Schwabenheim/D |
|
LMP4 | ß-Lactones as a new class of anti-virulence drugs |
V. Korotkov, Ludwig-Maximilians-Universität München, Garching/D; E. Zeiler, TU München, Garching/D; K. Lorenz-Baath, T. Böttcher, Ludwig-Maximilians-Universität München, Garching/D; S. Sieber, TU München, Garching/D |
|
LMP5 | EU-OPENSCREEN - A European infrastructure of open screening platforms for chemical biology |
B. Stechmann, R. Frank, EU-OPENSCREEN / FMP Leibniz-Institut für Molekulare Pharmakologie, Berlin/D |
|
LMP6 | Development of helix-mimetic scaffolds as potential disruptors of PKA-AKAP interactions |
G. Schaefer, MDC Berlin, FMP Berlin, FU Berlin/D; J. Milic, MDC Berlin, FMP Berlin/D; C. Schillinger, P. Schmieder, G. Krause, FMP Berlin/D; W. Rosenthal, MDC Berlin/D; J. Rademann, University of Leipzig/D; E. Klussmann, MDC Berlin/D |
|
LMP7 | Provision for enhanced reaction conditions under continuous flow: Eschenmoser coupling |
S. Singh, A. Schober, G. A. Groß, TU Ilmenau/D |
|
LMP8 | Drug-protein interactions probed by Capture Compound Mass Spectrometry (CCMS) |
J.J. Fischer, S. Michaelis, C. Dalhoff, O.Y. Graebner, K. Bartho, A.K. Schrey, caprotec bioanalytics GmbH, Berlin/D; A. Diehl, Leibniz-Institut fuer Molekulare Pharmakologie, Berlin/D; F. Kroll, M. Sefkow, S. Baumgart, M. Glinski, H. Koester, M. Dreger, caprotec bioanalytics GmbH, Berlin/D |
|
LMP9 | Development of homogeneous proximity assays for JMJD2A/2C histone demethylases |
A. Rodenbrock, M. Roy, L. Pedro, N. Gauthier, A. Labonte, V. Paquet, PerkinElmer, Montreal/CDN; M. Lässle, PerkinElmer, Rodgau/D; L. Beaudet, R. Rodriguez-Suarez, PerkinElmer, Montreal/CDN |
|
LMP10 | Thiol-tagged D-/L-peptides for dynamic covalent capture and informed antimicrobial peptide library design |
K.B. Jadhav, FSU, Jena/D; R.J. Lichtenecker, B. Ellinger, H.-M. Han, A. Bullach, M. Grabenbauer, MPI-MP, Dortmund/D; H.-D. Arndt, FSU, Jena/D |
|
LMP11 | Pharmacological inhibition of LIM kinase stabilizes microtubules and suppresses tumor growth |
R. Prudent, INSERM, La Tronche/F |
|
LMP12 | Targeting AKAP-PKA interactions with small molecules as a new concept for the treatment of heart failure |
A. Eldahshan, J. Milic, K. Zülke, F. Goetz, Max Delbrück Center for Molecular Medicine, Berlin/D; J-P. von Kries, Forschungsinstitut für Molekulare Pharmakologie, Berlin/D; W. Rosenthal, E. Klussmann, Max Delbrück Center for Molecular Medicine, Berlin/D |
|
LMP13 | Development of a tumour microenvironment mimicking 3D co-culture assay for drug discovery |
E. Krausz, Janssen Research & Development, Beerse/B |
|
LMP14 | From phenotype to mode of action: cellular impedance measurements for target discovery of bioactive compounds |
R. Franke, T. Schneider, T. Schulze, F. Sasse, Helmholtz Centre for Infection Research GmbH, Braunschweig/D |
DECHEMA -AG Tagungen- |
-Daniela Sabolo- |
Telefon: 069 / 75 64- 243 Telefax: 069 / 75 64- 176 |